Literature DB >> 33692208

A vulnerable, membrane-proximal site in human respiratory syncytial virus F revealed by a prefusion-specific single-domain antibody.

Iebe Rossey1,2,3, Ching-Lin Hsieh4, Koen Sedeyn1,2,3, Marlies Ballegeer1,2,3, Bert Schepens1,2,3, Jason S Mclellan4, Xavier Saelens5,2,3.   

Abstract

Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease, especially in young children and the elderly. The fusion protein (F) exists in a pre- and postfusion conformation and is the main target of RSV-neutralizing antibodies. Highly potent RSV-neutralizing antibodies typically bind sites that are unique to the prefusion conformation of F. In this study we screened a single-domain antibody (VHH) library derived from a llama immunized with prefusion-stabilized F and identified a prefusion F-specific VHH that can neutralize RSV A at subnanomolar concentrations. Structural analysis revealed that this VHH primarily binds to antigenic site I while also making contacts with residues in antigenic site III and IV. This new VHH reveals a previously underappreciated membrane-proximal region sensitive for neutralization.ImportanceRSV is an important respiratory pathogen. This study describes a prefusion F-specific VHH that primarily binds to antigenic site I of RSV F. This is the first time that a prefusion F-specific antibody that binds this site is reported. In general, antibodies that bind to site I are poorly neutralizing, whereas the VHH described here neutralizes RSV A at subnanomolar concentrations. Our findings contribute to insights into the RSV F antigenic map.
Copyright © 2021 American Society for Microbiology.

Entities:  

Year:  2021        PMID: 33692208      PMCID: PMC8139709          DOI: 10.1128/JVI.02279-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics.

Authors:  Lydia Tan; Frank E J Coenjaerts; Lieselot Houspie; Marco C Viveen; Grada M van Bleek; Emmanuel J H J Wiertz; Darren P Martin; Philippe Lemey
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

2.  A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates.

Authors:  Jennifer R Keeffe; Koen K A Van Rompay; Priscilla C Olsen; Qiao Wang; Anna Gazumyan; Stephanie A Azzopardi; Dennis Schaefer-Babajew; Yu E Lee; Jackson B Stuart; Anil Singapuri; Jennifer Watanabe; Jodie Usachenko; Amir Ardeshir; Mohsan Saeed; Marianna Agudelo; Thomas Eisenreich; Stylianos Bournazos; Thiago Y Oliveira; Charles M Rice; Lark L Coffey; Margaret R MacDonald; Pamela J Bjorkman; Michel C Nussenzweig; Davide F Robbiani
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

3.  Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.

Authors:  Jason S McLellan; Man Chen; M Gordon Joyce; Mallika Sastry; Guillaume B E Stewart-Jones; Yongping Yang; Baoshan Zhang; Lei Chen; Sanjay Srivatsan; Anqi Zheng; Tongqing Zhou; Kevin W Graepel; Azad Kumar; Syed Moin; Jeffrey C Boyington; Gwo-Yu Chuang; Cinque Soto; Ulrich Baxa; Arjen Q Bakker; Hergen Spits; Tim Beaumont; Zizheng Zheng; Ningshao Xia; Sung-Youl Ko; John-Paul Todd; Srinivas Rao; Barney S Graham; Peter D Kwong
Journal:  Science       Date:  2013-11-01       Impact factor: 47.728

Review 4.  Clinical Potential of Prefusion RSV F-specific Antibodies.

Authors:  Iebe Rossey; Jason S McLellan; Xavier Saelens; Bert Schepens
Journal:  Trends Microbiol       Date:  2017-10-17       Impact factor: 17.079

5.  Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.

Authors:  Ellen J Collarini; F Eun-Hyung Lee; Orit Foord; Minha Park; Gizette Sperinde; Hai Wu; William D Harriman; Stephen F Carroll; Stote L Ellsworth; Larry J Anderson; Ralph A Tripp; Edward E Walsh; Bruce A Keyt; Lawrence M Kauvar
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

6.  High efficiency transformation by electroporation of Pichia pastoris pretreated with lithium acetate and dithiothreitol.

Authors:  Shixuan Wu; Geoffrey J Letchworth
Journal:  Biotechniques       Date:  2004-01       Impact factor: 1.993

7.  Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein.

Authors:  Morgan S A Gilman; Syed M Moin; Vicente Mas; Man Chen; Nita K Patel; Kari Kramer; Qing Zhu; Stephanie C Kabeche; Azad Kumar; Concepción Palomo; Tim Beaumont; Ulrich Baxa; Nancy D Ulbrandt; José A Melero; Barney S Graham; Jason S McLellan
Journal:  PLoS Pathog       Date:  2015-07-10       Impact factor: 6.823

8.  Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.

Authors:  Xiaolin Wen; Jarrod J Mousa; John T Bates; Robert A Lamb; James E Crowe; Theodore S Jardetzky
Journal:  Nat Microbiol       Date:  2017-01-30       Impact factor: 17.745

9.  A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein.

Authors:  Aimin Tang; Zhifeng Chen; Kara S Cox; Hua-Poo Su; Cheryl Callahan; Arthur Fridman; Lan Zhang; Sangita B Patel; Pedro J Cejas; Ryan Swoyer; Sinoeun Touch; Michael P Citron; Dhanasekaran Govindarajan; Bin Luo; Michael Eddins; John C Reid; Stephen M Soisson; Jennifer Galli; Dai Wang; Zhiyun Wen; Gwendolyn J Heidecker; Danilo R Casimiro; Daniel J DiStefano; Kalpit A Vora
Journal:  Nat Commun       Date:  2019-09-12       Impact factor: 14.919

10.  Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.

Authors:  Alina Baum; Benjamin O Fulton; Elzbieta Wloga; Richard Copin; Kristen E Pascal; Vincenzo Russo; Stephanie Giordano; Kathryn Lanza; Nicole Negron; Min Ni; Yi Wei; Gurinder S Atwal; Andrew J Murphy; Neil Stahl; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

View more
  2 in total

Review 1.  Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections.

Authors:  Keke Huang; Tianlei Ying; Yanling Wu
Journal:  Viruses       Date:  2022-05-27       Impact factor: 5.818

2.  Monoterpene-Containing Substituted Coumarins as Inhibitors of Respiratory Syncytial Virus (RSV) Replication.

Authors:  Tatyana M Khomenko; Anna A Shtro; Anastasia V Galochkina; Yulia V Nikolaeva; Galina D Petukhova; Sophia S Borisevich; Dina V Korchagina; Konstantin P Volcho; Nariman F Salakhutdinov
Journal:  Molecules       Date:  2021-12-10       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.